Skip to Content

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

Results from the AVENANCE trial suggest that avelumab may provide a promising maintenance treatment option for patients with low-burden urothelial carcinoma, showing encouraging survival and progression-free survival outcomes after chemotherapy.

Philippe Barthélémy

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top